Clinical Trial Update: Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating oral deforolimus in combination with trastuzumab for HER2-positive trastuzumab-refractory metastatic breast cancer has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Deforolimus (ridaforolimus)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Cancer, Breast Neoplasms | Phase 2 | Status: COMPLETED